Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 61 entries
Sorted by: Best Match Show Resources per page
The Effects of Stress Exposure on Prefrontal Cortex: Translating Basic Research into Successful Treatments for Post-Traumatic Stress Disorder.

Neurobiology of stress

Arnsten AF, Raskind MA, Taylor FB, Connor DF.
PMID: 25436222
Neurobiol Stress. 2015 Jan 01;1:89-99. doi: 10.1016/j.ynstr.2014.10.002.

Research on the neurobiology of the stress response in animals has led to successful new treatments for Post-Traumatic Stress Disorder (PTSD) in humans. Basic research has found that high levels of catecholamine release during stress rapidly impair the top-down...

Cite
Arnsten AF, Raskind MA, Taylor FB, et al. The Effects of Stress Exposure on Prefrontal Cortex: Translating Basic Research into Successful Treatments for Post-Traumatic Stress Disorder. Neurobiol Stress. 2015;1:89-99doi: 10.1016/j.ynstr.2014.10.002.
Arnsten, A. F., Raskind, M. A., Taylor, F. B., & Connor, D. F. (2015). The Effects of Stress Exposure on Prefrontal Cortex: Translating Basic Research into Successful Treatments for Post-Traumatic Stress Disorder. Neurobiology of stress, 189-99. https://doi.org/10.1016/j.ynstr.2014.10.002
Arnsten, Amy F T, et al. "The Effects of Stress Exposure on Prefrontal Cortex: Translating Basic Research into Successful Treatments for Post-Traumatic Stress Disorder." Neurobiology of stress vol. 1 (2015): 89-99. doi: https://doi.org/10.1016/j.ynstr.2014.10.002
Arnsten AF, Raskind MA, Taylor FB, Connor DF. The Effects of Stress Exposure on Prefrontal Cortex: Translating Basic Research into Successful Treatments for Post-Traumatic Stress Disorder. Neurobiol Stress. 2015 Jan 01;1:89-99. doi: 10.1016/j.ynstr.2014.10.002. PMID: 25436222; PMCID: PMC4244027.
Copy Download .nbib Format: NLM
Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder.

Neuropsychiatric disease and treatment

Martinez-Raga J, Knecht C, de Alvaro R.
PMID: 26064054
Neuropsychiatr Dis Treat. 2015 May 28;11:1359-70. doi: 10.2147/NDT.S65735. eCollection 2015.

The α2-adrenergic receptor agonist guanfacine, in its extended-release formulation (GXR), is the most recent nonstimulant medication approved in several countries for the treatment of attention-deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive pharmacotherapy to stimulants in children and...

Cite
Martinez-Raga J, Knecht C, de Alvaro R. Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. Neuropsychiatr Dis Treat. 2015;11:1359-70doi: 10.2147/NDT.S65735.
Martinez-Raga, J., Knecht, C., & de Alvaro, R. (2015). Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. Neuropsychiatric disease and treatment, 111359-70. https://doi.org/10.2147/NDT.S65735
Martinez-Raga, Jose, et al. "Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder." Neuropsychiatric disease and treatment vol. 11 (2015): 1359-70. doi: https://doi.org/10.2147/NDT.S65735
Martinez-Raga J, Knecht C, de Alvaro R. Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. Neuropsychiatr Dis Treat. 2015 May 28;11:1359-70. doi: 10.2147/NDT.S65735. eCollection 2015. PMID: 26064054; PMCID: PMC4455846.
Copy Download .nbib Format: NLM
Adherence to EBM guidelines in clinical practice.

The International journal of risk & safety in medicine

Khafizianova RKh, Burykin IM.
PMID: 26639710
Int J Risk Saf Med. 2015;27:S53-4. doi: 10.3233/JRS-150687.

BACKGROUND: Adequate and rational pharmacotherapy is an important element of rehabilitation of patients with myocardial infarction. Orders of the Ministry of Health of the Russian Federation, domestic and international guidelines, and scientific publications - all contain a complete algorithm...

Cite
Khafizianova RKh, Burykin IM. Adherence to EBM guidelines in clinical practice. Int J Risk Saf Med. 2015;27:S53-4doi: 10.3233/JRS-150687.
Khafizianova, R. K. h., & Burykin, I. M. (2015). Adherence to EBM guidelines in clinical practice. The International journal of risk & safety in medicine, 27S53-4. https://doi.org/10.3233/JRS-150687
Khafizianova, R Kh, and Burykin, I M. "Adherence to EBM guidelines in clinical practice." The International journal of risk & safety in medicine vol. 27 (2015): S53-4. doi: https://doi.org/10.3233/JRS-150687
Khafizianova RKh, Burykin IM. Adherence to EBM guidelines in clinical practice. Int J Risk Saf Med. 2015;27:S53-4. doi: 10.3233/JRS-150687. PMID: 26639710.
Copy Download .nbib Format: NLM
Stimulation of Alpha-Adrenoceptors Facilitates the Release of Growth Hormone-Releasing Hormone from Rat Hypothalamus in vitro.

Journal of neuroendocrinology

Tsagarakis S, Ge F, Rees LH, Besser GM, Grossman A.
PMID: 19210470
J Neuroendocrinol. 1989 Apr 01;1(2):129-33. doi: 10.1111/j.1365-2826.1989.tb00091.x.

Abstract While extensive evidence suggests that adrenoceptors play an important role in the control of growth hormone in the rat, there are few studies involving the direct measurement of growth hormone-releasing hormone (GHRH). We have therefore developed a radioimmunoassay...

Cite
Tsagarakis S, Ge F, Rees LH, et al. Stimulation of Alpha-Adrenoceptors Facilitates the Release of Growth Hormone-Releasing Hormone from Rat Hypothalamus in vitro. J Neuroendocrinol. 1989;1(2):129-33doi: 10.1111/j.1365-2826.1989.tb00091.x.
Tsagarakis, S., Ge, F., Rees, L. H., Besser, G. M., & Grossman, A. (1989). Stimulation of Alpha-Adrenoceptors Facilitates the Release of Growth Hormone-Releasing Hormone from Rat Hypothalamus in vitro. Journal of neuroendocrinology, 1(2), 129-33. https://doi.org/10.1111/j.1365-2826.1989.tb00091.x
Tsagarakis, S, et al. "Stimulation of Alpha-Adrenoceptors Facilitates the Release of Growth Hormone-Releasing Hormone from Rat Hypothalamus in vitro." Journal of neuroendocrinology vol. 1,2 (1989): 129-33. doi: https://doi.org/10.1111/j.1365-2826.1989.tb00091.x
Tsagarakis S, Ge F, Rees LH, Besser GM, Grossman A. Stimulation of Alpha-Adrenoceptors Facilitates the Release of Growth Hormone-Releasing Hormone from Rat Hypothalamus in vitro. J Neuroendocrinol. 1989 Apr 01;1(2):129-33. doi: 10.1111/j.1365-2826.1989.tb00091.x. PMID: 19210470.
Copy Download .nbib Format: NLM
Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

Behavioral and brain functions : BBF

Levy F.
PMID: 18304369
Behav Brain Funct. 2008 Feb 28;4:12. doi: 10.1186/1744-9081-4-12.

BACKGROUND: Recent directions in the treatment of ADHD have involved both a broadening of pharmacological perspectives to include nor-adrenergic as well as dopaminergic agents. A review of animal and human studies of pharmacological and therapeutic directions in ADHD suggests...

Cite
Levy F. Pharmacological and therapeutic directions in ADHD: Specificity in the PFC. Behav Brain Funct. 2008;4:12doi: 10.1186/1744-9081-4-12.
Levy, F. (2008). Pharmacological and therapeutic directions in ADHD: Specificity in the PFC. Behavioral and brain functions : BBF, 412. https://doi.org/10.1186/1744-9081-4-12
Levy, Florence. "Pharmacological and therapeutic directions in ADHD: Specificity in the PFC." Behavioral and brain functions : BBF vol. 4 (2008): 12. doi: https://doi.org/10.1186/1744-9081-4-12
Levy F. Pharmacological and therapeutic directions in ADHD: Specificity in the PFC. Behav Brain Funct. 2008 Feb 28;4:12. doi: 10.1186/1744-9081-4-12. PMID: 18304369; PMCID: PMC2289834.
Copy Download .nbib Format: NLM
Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders.

Current treatment options in neurology

Wink LK, Erickson CA, McDougle CJ.
PMID: 20848330
Curr Treat Options Neurol. 2010 Nov;12(6):529-38. doi: 10.1007/s11940-010-0091-8.

OPINION STATEMENT: Pervasive developmental disorders (PDDs), including autistic disorder (autism), Asperger's disorder, and pervasive developmental disorder not otherwise specified (PDD NOS), are neurodevelopmental disorders of childhood onset. These disorders persist throughout the lifespan of affected individuals and are characterized...

Cite
Wink LK, Erickson CA, McDougle CJ. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Curr Treat Options Neurol. 2010;12(6):529-38doi: 10.1007/s11940-010-0091-8.
Wink, L. K., Erickson, C. A., & McDougle, C. J. (2010). Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Current treatment options in neurology, 12(6), 529-38. https://doi.org/10.1007/s11940-010-0091-8
Wink, Logan K, et al. "Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders." Current treatment options in neurology vol. 12,6 (2010): 529-38. doi: https://doi.org/10.1007/s11940-010-0091-8
Wink LK, Erickson CA, McDougle CJ. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Curr Treat Options Neurol. 2010 Nov;12(6):529-38. doi: 10.1007/s11940-010-0091-8. PMID: 20848330.
Copy Download .nbib Format: NLM
Off-label Prescribing Trends for ADHD Medications in Very Young Children.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Panther SG, Knotts AM, Odom-Maryon T, Daratha K, Woo T, Klein TA.
PMID: 29290742
J Pediatr Pharmacol Ther. 2017 Nov-Dec;22(6):423-429. doi: 10.5863/1551-6776-22.6.423.

OBJECTIVE: This study examines off-label medication prescribing use and trends in children on Medicaid with ADHD with particular focus on the very young (under age 6 years).METHODS: This was an observational cohort study and retrospective analysis of ADHD medication...

Cite
Panther SG, Knotts AM, Odom-Maryon T, et al. Off-label Prescribing Trends for ADHD Medications in Very Young Children. J Pediatr Pharmacol Ther. 2017;22(6):423-429doi: 10.5863/1551-6776-22.6.423.
Panther, S. G., Knotts, A. M., Odom-Maryon, T., Daratha, K., Woo, T., & Klein, T. A. (2017). Off-label Prescribing Trends for ADHD Medications in Very Young Children. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 22(6), 423-429. https://doi.org/10.5863/1551-6776-22.6.423
Panther, Shannon G, et al. "Off-label Prescribing Trends for ADHD Medications in Very Young Children." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 22,6 (2017): 423-429. doi: https://doi.org/10.5863/1551-6776-22.6.423
Panther SG, Knotts AM, Odom-Maryon T, Daratha K, Woo T, Klein TA. Off-label Prescribing Trends for ADHD Medications in Very Young Children. J Pediatr Pharmacol Ther. 2017 Nov-Dec;22(6):423-429. doi: 10.5863/1551-6776-22.6.423. PMID: 29290742; PMCID: PMC5736254.
Copy Download .nbib Format: NLM
Guanfacine hydrochloride for attention deficit hyperactivity disorder.

Australian prescriber

[No authors listed]
PMID: 30116086
Aust Prescr. 2018 Aug;41(4):131-132. doi: 10.18773/austprescr.2018.042. Epub 2018 Jun 27.

No abstract available.

Cite
Guanfacine hydrochloride for attention deficit hyperactivity disorder. Aust Prescr. 2018;41(4):131-132doi: 10.18773/austprescr.2018.042.
(2018). Guanfacine hydrochloride for attention deficit hyperactivity disorder. Australian prescriber, 41(4), 131-132. https://doi.org/10.18773/austprescr.2018.042
"Guanfacine hydrochloride for attention deficit hyperactivity disorder." Australian prescriber vol. 41,4 (2018): 131-132. doi: https://doi.org/10.18773/austprescr.2018.042
Guanfacine hydrochloride for attention deficit hyperactivity disorder. Aust Prescr. 2018 Aug;41(4):131-132. doi: 10.18773/austprescr.2018.042. Epub 2018 Jun 27. PMID: 30116086; PMCID: PMC6091781.
Copy Download .nbib Format: NLM
Social defeat-induced anhedonia: effects on operant sucrose-seeking behavior.

Frontiers in behavioral neuroscience

Riga D, Theijs JT, De Vries TJ, Smit AB, Spijker S.
PMID: 26300748
Front Behav Neurosci. 2015 Aug 07;9:195. doi: 10.3389/fnbeh.2015.00195. eCollection 2015.

Reduced capacity to experience pleasure, also known as anhedonia, is a key feature of the depressive state and is associated with poor disease prognosis and treatment outcome. Various behavioral readouts (e.g., reduced sucrose intake) have been employed in animal...

Cite
Riga D, Theijs JT, De Vries TJ, et al. Social defeat-induced anhedonia: effects on operant sucrose-seeking behavior. Front Behav Neurosci. 2015;9:195doi: 10.3389/fnbeh.2015.00195.
Riga, D., Theijs, J. T., De Vries, T. J., Smit, A. B., & Spijker, S. (2015). Social defeat-induced anhedonia: effects on operant sucrose-seeking behavior. Frontiers in behavioral neuroscience, 9195. https://doi.org/10.3389/fnbeh.2015.00195
Riga, Danai, et al. "Social defeat-induced anhedonia: effects on operant sucrose-seeking behavior." Frontiers in behavioral neuroscience vol. 9 (2015): 195. doi: https://doi.org/10.3389/fnbeh.2015.00195
Riga D, Theijs JT, De Vries TJ, Smit AB, Spijker S. Social defeat-induced anhedonia: effects on operant sucrose-seeking behavior. Front Behav Neurosci. 2015 Aug 07;9:195. doi: 10.3389/fnbeh.2015.00195. eCollection 2015. PMID: 26300748; PMCID: PMC4528167.
Copy Download .nbib Format: NLM
A case of sinus pause induced by swallowing in the setting of olanzapine and guanfacine overdose.

Journal of the Intensive Care Society

Kolarich AR, Mubarak M, Wells S, Campbell CT, Samraj RS.
PMID: 31447925
J Intensive Care Soc. 2019 Aug;20(3):277-280. doi: 10.1177/1751143718786109. Epub 2018 Jul 05.

Olanzapine, a second-generation antipsychotic, is used in both adult and pediatric populations for schizophrenia, bipolar disorder, and depression and has been associated with autonomic dysregulation in the setting of overdose. Guanfacine is a sympatholytic drug used in the treatment...

Cite
Kolarich AR, Mubarak M, Wells S, et al. A case of sinus pause induced by swallowing in the setting of olanzapine and guanfacine overdose. J Intensive Care Soc. 2018;20(3):277-280doi: 10.1177/1751143718786109.
Kolarich, A. R., Mubarak, M., Wells, S., Campbell, C. T., & Samraj, R. S. (2019). A case of sinus pause induced by swallowing in the setting of olanzapine and guanfacine overdose. Journal of the Intensive Care Society, 20(3), 277-280. https://doi.org/10.1177/1751143718786109
Kolarich, Andrew R, et al. "A case of sinus pause induced by swallowing in the setting of olanzapine and guanfacine overdose." Journal of the Intensive Care Society vol. 20,3 (2019): 277-280. doi: https://doi.org/10.1177/1751143718786109
Kolarich AR, Mubarak M, Wells S, Campbell CT, Samraj RS. A case of sinus pause induced by swallowing in the setting of olanzapine and guanfacine overdose. J Intensive Care Soc. 2019 Aug;20(3):277-280. doi: 10.1177/1751143718786109. Epub 2018 Jul 05. PMID: 31447925; PMCID: PMC6693107.
Copy Download .nbib Format: NLM
Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Short Communication.

Therapeutic drug monitoring

Wohkittel C, Scherf-Clavel O, Fekete S, Romanos M, Högger P, Gerlach M.
PMID: 34334681
Ther Drug Monit. 2021 Jul 30; doi: 10.1097/FTD.0000000000000917. Epub 2021 Jul 30.

BACKGROUND: Guanfacine, a selective α2A-adrenoreceptor agonist, is a second-line medication for treating children and adolescents with attention-deficit/hyperkinetic disorder (ADHD). The dosage administered as milligram per body weight to balance the potential benefits and risks of treatment. Therapeutic drug monitoring...

Cite
Wohkittel C, Scherf-Clavel O, Fekete S, et al. Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Short Communication. Ther Drug Monit. 2021;doi: 10.1097/FTD.0000000000000917.
Wohkittel, C., Scherf-Clavel, O., Fekete, S., Romanos, M., Högger, P., & Gerlach, M. (2021). Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Short Communication. Therapeutic drug monitoring, . https://doi.org/10.1097/FTD.0000000000000917
Wohkittel, Christopher, et al. "Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Short Communication." Therapeutic drug monitoring vol. (2021). doi: https://doi.org/10.1097/FTD.0000000000000917
Wohkittel C, Scherf-Clavel O, Fekete S, Romanos M, Högger P, Gerlach M. Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Short Communication. Ther Drug Monit. 2021 Jul 30; doi: 10.1097/FTD.0000000000000917. Epub 2021 Jul 30. PMID: 34334681.
Copy Download .nbib Format: NLM
Two Sisters From Qatar With TUSC3 Genetic Mutation: Psychiatric Considerations.

Cureus

Albobali Y, Shahwan MY, Madi MY, Al-Nuaimi S.
PMID: 34646667
Cureus. 2021 Aug 31;13(8):e17616. doi: 10.7759/cureus.17616. eCollection 2021 Aug.

Defects in the tumor suppressor candidate 3 (TUSC3) gene have been identified in individuals with autosomal recessive intellectual disability (ARID). Our report on two sisters from Qatar with a mutation in the TUSC3 gene focuses on the behavioral manifestations...

Cite
Albobali Y, Shahwan MY, Madi MY, et al. Two Sisters From Qatar With TUSC3 Genetic Mutation: Psychiatric Considerations. Cureus. 2021;13(8):e17616doi: 10.7759/cureus.17616.
Albobali, Y., Shahwan, M. Y., Madi, M. Y., & Al-Nuaimi, S. (2021). Two Sisters From Qatar With TUSC3 Genetic Mutation: Psychiatric Considerations. Cureus, 13(8), e17616. https://doi.org/10.7759/cureus.17616
Albobali, Yahia, et al. "Two Sisters From Qatar With TUSC3 Genetic Mutation: Psychiatric Considerations." Cureus vol. 13,8 (2021): e17616. doi: https://doi.org/10.7759/cureus.17616
Albobali Y, Shahwan MY, Madi MY, Al-Nuaimi S. Two Sisters From Qatar With TUSC3 Genetic Mutation: Psychiatric Considerations. Cureus. 2021 Aug 31;13(8):e17616. doi: 10.7759/cureus.17616. eCollection 2021 Aug. PMID: 34646667; PMCID: PMC8483409.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 61 entries